Results 11 to 20 of about 4,230 (200)

5-HT₃ receptor antagonists for preventing postoperative nausea and vomiting after gynecological surgery: A systematic review and network meta-analysis. [PDF]

Int J Gynaecol Obstet
Abstract Background Gynecological surgery is generally associated with a high risk of postoperative nausea and vomiting (PONV), for which a combination of antiemetic therapies is advised, but adherence to these protocols is often low. Given the current reality, a preferred 5‐HT3 receptor antagonist for preventing PONV as a result of gynecological ...
Xu H, Rong L, Yang S, Xing J, Dong H, Liu H, Chen X, Liu L.   +7 more
europepmc   +2 more sources

Comparative Study of Ondansetron and Palonosetron for Prevention of Nausea and Vomiting Following Upper Abdominal Surgeries under General Anaesthesia: A Randomised Control Trial [PDF]

Journal of Clinical and Diagnostic Research, 2020
Introduction: Postoperative Nausea and Vomiting (PONV) is a common entity following surgical procedure. It may result into serious complication like aspiration of gastric contents, prolonged recovery period.
Deepak Premnarayan Gupta, Vijay Chandak
doaj   +1 more source

Aprepitant in combination with palonosetron for the prevention of postoperative nausea and vomiting in female patients using intravenous patient-controlled analgesia [PDF]

Korean Journal of Anesthesiology, 2018
Background The aim of this study was to evaluate aprepitant in combination with palonosetron as compared to palonosetron alone for the prevention of postoperative nausea and vomiting (PONV) in female patients receiving fentanyl- based intravenous patient-
Jae Hwa Yoo, Soon Im Kim, Ji Won Chung, Mi Roung Jun, Yoo Mi Han, Yong Jik Kim   +5 more
doaj   +1 more source

Stability indicating Rp-UPLC method development and validation for the simultaneous estimation of fosnetupitant and palonosetron in bulk and injection dosage form [PDF]

Brazilian Journal of Pharmaceutical Sciences, 2022
A stability indicating UPLC method has been developed and validated for the simultaneous determination of fosnetupitant and palonosetron in bulk and in injection dosage form.
Poojari Venkatesh, Umasankar Kulandaivelu, GSN Koteswara Rao, Guntupalli Chakravarthi, Rajasekhar Reddy Alavala, Bandlamuri Rajesh   +5 more
doaj   +1 more source

Applicability of the National Comprehensive Cancer Network/Multinational Association of Supportive Care in Cancer Guidelines for Prevention and Management of Chemotherapy-Induced Nausea and Vomiting in Southeast Asia: A Consensus Statement. [PDF]

, 2017
A meeting of regional experts was convened in Manila, Philippines, to develop a resource-stratified chemotherapy-induced nausea and vomiting (CINV) management guideline. In patients treated with highly emetogenic chemotherapy in general clinical settings,
Abdullah, Matin M, Chan, Alexandre, Ishak, Wan Zamaniah B Wan, Kanesvaran, Ravindran, Ong-Cornel, Annielyn B, Villalon, Antonio H   +5 more
core   +2 more sources

Every‐other‐day palonosetron plus aprepitant for prevention of emesis following induction chemotherapy for acute myeloid leukemia: A randomized, controlled study from the “Rete Ematologica Pugliese”

Cancer Medicine, 2020
Background Compared with older 5‐HT3 receptor antagonists, palonosetron requires fewer drug administrations to prevent chemotherapy‐induced nausea and vomiting (CINV) following multiple‐day chemotherapy.
Nicola Di Renzo, Lorella Melillo, Fernando Porretto, Michela Dargenio, Vincenzo Pavone, Domenico Pastore, Patrizio Mazza, Donato Mannina, Anxur Merenda, Nicola Cascavilla, Giuseppina Greco, Rosella Matera, Erminio Bonizzoni, Luigi Celio, Maurizio Musso   +14 more
doaj   +1 more source

Comparison of palonosetron with ondansetron in prevention of postoperative nausea and vomiting in patients receiving intravenous patient-controlled analgesia after gynecological laparoscopic surgery [PDF]

Korean Journal of Anesthesiology, 2013
BackgroundPostoperative nausea and vomiting (PONV) are common complications after anesthesia and surgery. This study was designed to compare the effects of palonosetron and ondansetron in preventing PONV in high-risk patients receiving intravenous opioid-
Yu Yil Kim, Soo Yeong Moon, Dong Un Song, Ki Hyun Lee, Jae Wook Song, Young Eun Kwon   +5 more
doaj   +1 more source

5-hydroxytryptamine (5-HT) cellular sequestration during chronic exposure delays 5-HT₃ receptor resensitization due to Its subsequent release [PDF]

, 2014
The serotonergic synapse is dynamically regulated by serotonin (5-hydroxytryptamine (5-HT)) with elevated levels leading to the down-regulation of the serotonin transporter and a variety of 5-HT receptors, including the 5-HT type-3 (5-HT(3)) receptors ...
Aapro, Ahern, Amy Alexander, Andrew J. Samson, Bearcroft, Bertrand, Bertrand, Bhattacharyya, Boyd, Chanrion, Chen, Chen, Christopher Moffat, Christopher N. Connolly, Connolly, Craig, Faerber, Freeman, Galligan, Guthrie, Hagbom, Hanley, Hansen, Hothersall, Huang, Ilegems, J. Daniel Hothersall, Jiménez-Trejo, Karen A. Bollan, Kittler, Kondaurova, Lau, Lee, Linder, Liu, Liu, Lummis, McKinnon, Mercado, Minami, Mnie-Filali, Muchatuta, Niesler, Riad, Rojas, Schlag, Spiller, Stratz, Tao-Cheng, Turvill, Vikenes, Wade, Wesseldijk, Whalen, Yasuda   +54 more
core   +3 more sources

NEPA (Netupitant/Palonosetron) for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients Receiving Highly or Moderately Emetogenic Chemotherapy Who Experienced Breakthrough CINV in Cycle 1 of Chemotherapy: A Phase II Clinical Trial. [PDF]

Cancer Med
This study was designed to evaluate the use of NEPA (netupitant/palonosetron) plus dexamethasone with or without olanzapine for the prevention of CINV in the second cycle of chemotherapy for patients receiving highly (HEC) or moderately emetogenic chemotherapy (MEC) who developed breakthrough CINV in their first cycle despite guideline‐directed ...
Navari RM, Bonizzoni E.
europepmc   +2 more sources

Randomized pharmacokinetic study comparing subcutaneous and intravenous palonosetron in cancer patients treated with platinum based chemotherapy.

PLoS ONE, 2014
BackgroundPalonosetron is a potent second generation 5- hydroxytryptamine-3 selective antagonist which can be administered by either intravenous (IV) or oral routes, but subcutaneous (SC) administration of palonosetron has never been studied, even though
Belen Sadaba, Anabel del Barrio, Miguel Angel Campanero, Jose Ramon Azanza, Almudena Gomez-Guiu, Jose Maria Lopez-Picazo, Salvador Martin Algarra, Francisco Guillén Grimá, Maria Blanco Prieto, Jose Luis Perez-Gracia, Alfonso Gurpide   +10 more
doaj   +1 more source